Histone deacetylase inhibitors potentiate tnf-related apoptosis-inducing ligand (Trail)-induced apoptosis in lymphoid malignancies

Cell Death and Differentiation

Volumn 11, Issue , 2004, Pages S193-S206

  Inoue, S ^a   Macfarlane, M ^a   Harper, N ^a   Wheat, L M C ^a   Dyer, M J S ^a   Cohen, G M ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Chronic lymphocytic leukemia; Depsipeptide; Disc; Histone deacetlyase inhibitors; Tumor necrosis factorrelated apoptosis inducing ligand

Indexed keywords

CASPASE 8; DEATH RECEPTOR 5; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SENSITIZATION; SIGNAL TRANSDUCTION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 8; CASPASES; CELL LINE, TUMOR; CYCLOHEXIMIDE; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DEPSIPEPTIDES; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; JURKAT CELLS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 12744261484     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401535     Document Type: Article

References (68)

1. Bratton SB, MacFarlane M, Cain K and Cohen GM (2000) Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp. Cell. Res. 256: 27-33
2. Reed JC (2000) Mechanisms of apoptosis. Am. J. Pathol. 157: 1415-1430
3. Chinnaiyan AM, O’Rourke K, Tewari M and Dixit VM (1995) FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512
4. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH and Peter ME (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14: 5579-5588
5. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J and Tschopp J (2000) TRAIL receptor-2 signals apoptosis through FADD and caspase-Nat. Cell. Biol. 2: 241-243
6. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ and Ashkenazi A (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and Immunity 12: 611-620
7. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH and Walczak H (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor Immunity 12: 599-609
8. Boldin MP, Goncharov TM, Goltsev YV and Wallach D (1996) Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85: 803-815
9. Muzio M, Chinnaiyan AM, Kischkel FC, O’Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME and Dixit VM (1996) FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85: 817-827
10. Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, Goddard AD, Bauer KD and Ashkenazi A (1996) Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NFkappa B. Curr. Biol. 6: 1669-1676
11. Wiley SR, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA and Goodwin RG (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682
12. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5: 157-163
13. Ashkenazi A and Dixit VM (1998) Death receptors: signaling and modulation. Science 281: 1305-1308
14. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE and Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195
15. Scaffidi C, Schmitz I, Krammer PH and Peter ME (1999) The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 274: 1541-1548
16. Krueger A, Schmitz I, Baumann S, Krammer PH and Kirchhoff S (2001) Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 276: 20633-20640
17. Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ and Bensa JC (1998) Tumor B cells from non-Hodgkin’s lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 91: 2875-2885
18. Xerri L, Devilard E, Hassoun J, Haddad P and Birg F (1997) Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis. Leukemia 11: 1868-1877
19. Xerri L, Bouabdallah R, Devilard E, Hassoun J, Stoppa AM and Birg F (1998) Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin’s lymphomas and is moderately increased by CD40 ligation. Br. J. Cancer 78: 225-232
20. MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH and Cohen GM (2002) Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21: 6809-6818
21. Wang D, Freeman GJ, Levine H, Ritz J and Robertson MJ (1997) Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br. J. Haematol. 97: 409-417
22. Ozoren N and El-Deiry WS (2003) Cell surface death receptor signaling in normal and cancer cells. Semin. Cancer Biol. 13: 135-147
23. Wajant H, Pfizenmaier K and Scheurich P (2002) TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 7: 449-459
24. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1: 287-299
25. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1: 194-202
26. Melnick A and Licht JD (2002) Histone deacetylases as therapeutic targets in hematologic malignancies. Curr. Opin. Hematol. 9: 322-332
27. Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, Lucas DM, Reed JC, Grever MR and Byrd JC (2003) Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102: 652-658
28. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C and Brancolini C (2003) Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J. Biol. Chem. 278: 12579-12589
29. Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW and Han JW (2002) Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem. 277: 2073-2080
30. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ and Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 98: 10833-10838
31. Bernhard D, Skvortsov S, Tinhofer I, Hubl H, Greil R, Csordas A and Kofler R (2001) Inhibition of histone deacetylase activity enhances Fas receptormediated apoptosis in leukemic lymphoblasts. Cell Death Differ. 8: 1014-1021
32. Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM and La Quaglia MP (1999) Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res. 59: 4392-4399
33. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA and Anderson KC (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101: 4055-4062
34. Neuzil J, Swettenham E and Gellert N (2004) Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL downregulation. Biochem. Biophys. Res. Commun. 314: 186-191
35. Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH and Evers BM (2001) Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 130: 265-272
36. Inoue H, Shiraki K, Ohmori S, Sakai T, Deguchi M, Yamanaka T, Okano H and Nakano T (2002) Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Int. J. Mol. Med. 9: 521-525
37. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M and Younes A (1997) Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br. J. Haematol. 99: 618-624
38. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA and Grever MR (1999) Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94: 1401-1408
39. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Xanthoudakis S, Roy S, Black C, Grimm E, Aspiotis R, Han Y, Nicholson DW and Karl IE (2000) Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat. Immunol. 1: 496-501
40. Srinivasula SM, Ahmad M, Fernandes-Alnemri T and Alnemri ES (1998) Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell 1: 949-957
41. MacFarlane M, Cohen GM and Dickens M (2000) JNK (c-Jun N-terminal kinase) and p38 activation in receptor-mediated and chemically-induced apoptosis of T-cells: differential requirements for caspase activation. Biochem. J. 348 (Part 1): 93-101
42. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Litwack G and Alnemri ES (1996) Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc. Natl. Acad. Sci. USA 93: 14486-14491
43. Bonavida B, Ng CP, Jazirehi A, Schiller G and Mizutani Y (1999) Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). Int. J. Oncol. 15: 793-802
44. Fulda S and Debatin KM (2003) Death receptor signaling in cancer therapy. Curr. Med. Chem. Anti-Cancer Agents 3: 253-262
45. Krueger A, Baumann S, Krammer PH and Kirchhoff S (2001) FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol. Cell. Biol. 21: 8247-8254
46. Harper N, Farrow SN, Kaptein A, Cohen GM and MacFarlane M (2001) Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappa B activation by inhibition of apical caspases. J. Biol. Chem. 276: 34743-34752
47. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D and Ashkenazi A (2002) Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 8: 274-281
48. Deng Y, Lin Y and Wu X (2002) TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16: 33-45
49. O’Reilly LA, Cullen L, Visvader J, Lindeman GJ, Print C, Bath ML, Huang DC and Strasser A (2000) The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. Am. J. Pathol. 157: 449-461
50. Reed JC (1998) Molecular biology of chronic lymphocytic leukemia. Semin. Oncol. 25: 11-18
51. Panayiotidis P, Ganeshaguru K, Foroni L and Hoffbrand AV (1995) Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia 9: 1227-1232
52. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P and Bhalla K (2004) Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligandinduced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 64: 2580-2589
53. Rosato RR, Almenara JA, Dai Y and Grant S (2003) Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2: 1273-1284
54. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA and Schrump DS (2002) Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR J. Natl. Cancer Inst. 94: 504-513
55. Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C, Frye R, Ploegh H, Kessler BM and Sinclair DA (2004) Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13: 627-638
56. Varadhachary AS, Edidin M, Hanlon AM, Peter ME, Krammer PH and Salgame P (2001) Phosphatidylinositol 30-kinase blocks CD95 aggregation and caspase- 8 cleavage at the death-inducing signaling complex by modulating lateral diffusion of CD J. Immunol. 166: 6564-6569
57. Algeciras-Schimnich A, Shen L, Barnhart BC, Murmann AE, Burkhardt JK and Peter ME (2002) Molecular ordering of the initial signaling events of CD Mol. Cell. Biol. 22: 207-220
58. Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, Rassenti L, Andreeff M, Bennett F, Sporn MB, Liotta LD, Kipps TJ and Reed JC (2002) The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood 100: 2965-2972
59. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, Adams JM and Strasser A (1999) Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286: 1735-1738
60. Ley R, Balmanno K, Hadfield K, Weston C and Cook SJ (2003) Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasomedependent degradation of the BH3-only protein, Bim. J. Biol. Chem. 278: 18811-18816
61. Ravi R and Bedi A (2002) Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res. 62: 1583-1587
62. Sun XM, Bratton SB, Butterworth M, MacFarlane M and Cohen GM (2002) Bcl- 2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-ofapoptosis protein. J. Biol. Chem. 277: 11345-11351
63. Harper N, Hughes M, MacFarlane M and Cohen GM (2003) Fas-associated death domain protein and caspase-8 are not recruited to the tumor necrosis factor receptor 1 signaling complex during tumor necrosis factor-induced apoptosis. J. Biol. Chem. 278: 25534-25541
64. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM and Alnemri ES (1997) Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 272: 25417-25420
65. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, Smith CA, Goodwin RG and Kubin MZ (1999) Functional analysis of TRAIL receptors using monoclonal antibodies. J. Immunol. 162: 2597-2605
66. Rasper DM, Vaillancourt JP, Hadano S, Houtzager VM, Seiden I, Keen SL, Tawa P, Xanthoudakis S, Nasir J, Martindale D, Koop BF, Peterson EP, Thornberry NA, Huang J, MacPherson DP, Black SC, Hornung F, Lenardo MJ, Hayden MR, Roy S and Nicholson DW (1998) Cell death attenuation by ‘Usurpin’, a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ. 5: 271-288
67. Snowden RT, Sun XM, Dyer MJ and Cohen GM (2003) Bisindolylmaleimide IX is a potent inducer of apoptosis in chronic lymphocytic leukaemic cells and activates cleavage of Mcl- Leukemia 17: 1981-1989
68. Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR and Cohen GM (1999) Distinct caspase cascades are initiated in receptor-mediated and chemicalinduced apoptosis. J. Biol. Chem. 274: 5053-5060